KHẢO SÁT TỶ LỆ NHIỄM EPSTEIN-BARR VIRUS (EBV) TRÊN UNG THƯ ĐẠI TRỰC TRÀNG

Abstract

Objective: To determine the prevalence of Epstein-Barr virus (EBV) infection in patients with primary colorectal cancer (CRC) who also had been identified KRAS mutations that is responsed to targeted therapy. Subjects and Methods: A cross-sectional study was conducted using 102 formalin-fixed paraffin-embedded (FFPE) samples derived from patients diagnosed with primary colorectal cancer (CRC) at Bach Mai Hospital between 2019 and 2020. Results: EBV infection was detected in 55 out of 102 cases, accounting for 53,9%. Among these, the proportion of patients harboring KRAS mutations was 49,02%, notably a significantly higher prevalence in females (p = 0,02). While EBV infection showed no association with age, sex, histopathological classification, or KRAS mutation status (p > 0,05). Conclusion: KRAS mutations responsed to targeted therapy were more frequently observed in female patients, while EBV infection was present in 53,9% of primary CRC cases, suggesting that EBV may be a high risk factor for CRC.